Hematology

Expert perspectives on the MAGNOLIA trial and novel BTK inhibitor zanubrutinib in the context of marginal zone lymphoma treatment.

FDA to evaluate luspatercept-aamt (Reblozyl) for the treatment of anemia in adults with non–transfusion dependent β-thalassemia.

FDA approves rituximab (Rituxan) plus chemotherapy for pediatric patients with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia.

Ibrutinib in combination with venetoclax shows promise in patients with previously untreated chronic lymphocytic leukemia.

The combination of daratumumab with hyaluronidase (Darzalex Faspro), hyaluronidase-fihj, carfilzomib (Kyprolis), and dexamethasone is indicated for the treatment of adult patients with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy.

Further, at daily doses of at least 100 mg, the rates of VTE with milvexian were significantly lower than with enoxaparin, according to the study authors.

A broad review of BTK inhibition as a novel therapeutic approach toward the treatment of marginal zone lymphoma.

Following discussion on the NCCN guidelines for second-line therapy in marginal zone lymphoma, experts highlight approved treatment options.

Besermi is an interferon alfa-2b indicated for the treatment of adults with polycythemia vera.

Within 1 or 2 days of injury, therapeutic B cells release a complex mix of specific pro- and anti-inflammatory molecules, which can affect molecular processing and facilitate healing.

Rituximab-pvvr is indicated for the treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, and granulomatosis.

Shared insight on treating marginal zone lymphoma with the current treatment armamentarium.

Expert panelists review the pathophysiology of marginal zone lymphoma and reflect on its prevalence as a rare disease.

Study finds COVID-19 booster shot was extremely beneficial for all patients with cancer, especially those with a blood cancer.

Hodgkin lymphoma is most common in people between 20 and 40 years of age and those over 55 years of age.

The panel also recommends considering risk factors for poor response, including uncontrolled disease, immunoparesis, the number of previous lines of therapy, and patient age.

Kymriah is a CD19-directed genetically modified autologous T-cell immunotherapy.

No new safety concerns were encountered, which the investigators said support the frontline use of daratumumab plus lenalidomide and dexamethasone for patients with multiple myeloma who are ineligible for transplantation.

Jennifer Andrews, MD, pediatric hematologist-oncologist at Vanderbilt University Medical Center and medical director of Vanderbilt University Medical Center’s blood bank, discusses what health systems can do to address the national blood shortage and increase blood donations.

Ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy is currently being evaluated for the treatment of patients with relapsed and/or refractory multiple myeloma.

Deep vein thrombosis can occur with certain medical conditions that affect how the blood clots.

Pembrolizumab (Keytruda) can be used for multiple cancer types, including melanoma, non-small cell lung cancer, and head and neck squamous cell cancer.

Asciminib (Scemblix) approved for patients with Philadelphia chromosome–positive chronic myeloid leukemia (CML) in chronic phase who were previously administered 2 or more tyrosine kinase inhibitors.

Patients undergoing chemotherapy had lower COVID-19 antibody levels than patients undergoing targeted therapy following vaccination.

Jennifer Andrews, MD, pediatric hematologist-oncologist at Vanderbilt University Medical Center and medical director of Vanderbilt University Medical Center’s blood bank, discusses how a national blood shortage could affect patient care and outcomes.